Table 3.
Subsequent systemic anti‐cancer therapy (Japanese ITT population)
|
Dacomitinib n = 40 |
Gefitinib n = 41 |
|
|---|---|---|
| Number of SSTs, n (%) | ||
| Any | 31 (77.5) | 35 (85.4) |
| 1 | 8 (20.0) | 13 (31.7) |
| 2 | 9 (22.5) | 5 (12.2) |
| 3 | 6 (15.0) | 7 (17.1) |
| >3 | 8 (20.0) | 10 (24.4) |
| Number of SSTs per patient | ||
| Number of patients with any SST, n | 31 | 35 |
| Mean | 2.7 | 2.8 |
| Median (range) | 2.0 (1‐7) | 2.0 (1‐8) |
| Time from last dose of study treatment to first SST, wk | ||
| Number of patients with any SST | 31 | 35 |
| Mean | 8.4 | 6.8 |
| Median (range) | 5.6 (0.3‐35.4) | 3.3 (0.3‐59.0) |
Cutoff date: February 17, 2017.
Abbreviation: SST, subsequent systemic anti‐cancer therapy.